| Literature DB >> 18371226 |
Zhixiang Peng1, Paula Fives-Taylor, Teresa Ruiz, Meixian Zhou, Baiming Sun, Qiang Chen, Hui Wu.
Abstract
BACKGROUND: Streptococcus parasanguinis is a primary colonizer of human tooth surfaces and plays an important role in dental plaque formation. Bacterial adhesion and biofilm formation are mediated by long peritrichous fimbriae that are composed of a 200 kDa serine rich glycoprotein named Fap1 (fimbriae-associated protein). Glycosylation and biogenesis of Fap1 are modulated by a gene cluster downstream of the fap1 locus. A gene encoding a glycosylation-associated protein, Gap3, was found to be important for Fap1 glycosylation, long fimbrial formation and Fap1-mediated biofilm formation.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18371226 PMCID: PMC2335109 DOI: 10.1186/1471-2180-8-52
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Alignment of Gap3 and its homologues. The black box represents identical or highly conserved residues. The gray box represents similar or less conserved residues. The red arrowed lines indicate the putatively important regions. The red numbers represent the residues chosen for site-directed mutagenesis. Gap3: glycosylation associated protein-3 of S. parasanguinis. Asp3: accessory secretory protein-3 of S. gordonii. SAG1450: hypothetical protein of S. agalactiae. SP1760: hypothetical protein of S. pneumoniae. SE2245: hypothetical protein of Staphylococcus epidermidis. gbs1519: hypothetical protein gbs1519 of S. agalactiae.
Figure 2Western blot analysis of expression of Fap1 and Gap3 variants. Gap3 deletion mutants, Δ62–67 mutant (Lane 1), Δ144–157 mutant (Lane 2), wild type strain (Lane 3), gap3 allelic replacement mutant VT1619 (Lane 4), gap3 complemented strain VT1732 (Lane 5) and a control strain (VT1619 transformed with empty vector pVT1666) (Lane 6) were subjected to Western blot analysis with the use of MAb D10 (A). Expression of Fap1 by Gap3 site-directed mutants, V33R, F35H, N37I, P38R, S42L, N54I, R59L, P62G, D63V, L64R, P65R, I66N, L67T and L75S (Lanes 1–14) and wild type strain (Lane 15) probed with MAb D10 (B) and MAb F51 (C). Expression of Gap3-GFP by gap3 site-directed mutants, Gap3 L64R (Lane 1), P65R (Lane 2), I66N (Lane3), L67T (Lane4), Gap3 complemented strain VT1732 (Lane 5), control (VT1619 with empty vector pVT1666) (Lane 6) and gap3 mutant VT1619 (Lane 7) probed with anti-GFP MAb (C). Gap3-GFP fusion proteins migrate at 48 kDa; GFP protein migrates at 27 kDa.
Figure 3Cell surface expression of Fap1 determined by BactELISA. MAbs F51 and E42 were used in BactELISA analysis to determine Fap1 expression in wild type FW213, fap1 mutant VT1393, gap3 mutant VT1619, gap3 complemented strain gap3-/gap3+ and Gap3 site-directed mutants, L64R, P65R, I66N and L67T. Data were obtained from three experiments in triplicates and are presented as means ± standard deviation.
Figure 4Electron micrographs of S. parasanguinis bacteria. S. parasanguinis bacteria, L64R (A), P65R (B), I66N (C), L67T (D) mutant variants and wild type FW213 (E) were placed on grids, and negatively stained with 2% phosphotungstic acid pH7.0 and visualized by electron microscopy. White arrows point to the short fimbriae. Black arrows point to the long fimbriae. Scale bar = 100 nm.
Figure 5Adhesion of S. parasanguinis to saliva-coated hydroxylapatite. Wild type of S. parasanguinis FW213, Gap3 site-directed mutants (L64R, P65R, I66N and L67T), fap1 mutant VT1393, gap3 mutant VT1619 and gap3 complemented strain gap3-/gap3+ were labeled with [3H] thymidine respectively. Labeled cells were incubated with SHA. The amounts of radioactivity associated with beads and supernatants were determined in a Wallac 1400 liquid scintillation counter and calculated to determine adhesion percentage. The data were obtained from three independent experiments in three replicates and are presented as means ± standard deviation.
Bacterial strains, plasmids and antibodies used in this study
| Strain, plasmid or antibody | Relevant characteristics | Reference or source |
| Strains | ||
| | ||
| FW213 | Wild type | [7] |
| VT1393 | [8] | |
| VT1619 | [23] | |
| VT1731 | pVT1666 into VT1619, vector control strain, ErmR & KanR | This study |
| VT1732 | pVT1732 into VT1619, | This study |
| VT1735 | Gap3 aa 62–67 encoding region deletion in pVT1732, ErmR &KanR | This study |
| VT1737 | Gap3 aa 144–157 encoding region deletion in pVT1732, ErmR &KanR | This study |
| VT1738 | Gap3 V33R mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1739 | Gap3 F35F mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1740 | Gap3 N37I mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1741 | Gap3 P38R mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1742 | Gap3 S42L mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1743 | Gap3 N54I mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1744 | Gap3 P62G mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1745 | Gap3 D63V mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1746 | Gap3 L64R mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1747 | Gap3 P65R mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1748 | Gap3 I66N mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1749 | Gap3 L67T mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1750 | Gap3 L75S mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| VT1751 | Gap3 R59L mutation of pVT1732 in VT1619, ErmR &KanR | This study |
| | ||
| DH10B | Host strain for cloning | Invitrogen |
| XL-10-Gold | Host strain for site-directed mutagenesis | Stratagene |
| Plasmids | ||
| pVT1571 | An | [11] |
| pVT1666 | PVT1571 vector contained | This study |
| pVT1732 | pVT1666 contained | This study |
| Antibodies | ||
| D10 | Partilly glycosylated Fap1 glycan epitope-specific MAb | [20] |
| E42 | Fap1 peptide epitope-specific MAb | [20] |
| F51 | Mature Fap1 glycan epitope-specific MAb | [20] |
| Anti-GFP | MAb against GFP tag | Roche Company |
Oligonucleotide primers used in this study
| Primer | Sequence | Reference or source |
| 5'-CGGCCGTCGACATGACTAAACAGTTAATTTC-3' | This study | |
| 5'-CGCCGCGGTACCAATATATTCTATTAAATTTTTC-3' | This study | |
| Δ62–67 Upstream | 5'-GCAGACTCGAGAGAATGACGATCACCTTG-3' | This study |
| Δ62–67 Downstream | 5'-CGGGCCTCGAGATACAAGGAAATAGATACCTTC-3' | This study |
| Δ144–157 Upstream | 5'-GCCCGCCCTCGAGATCATAAATCATAAATTTTTG-3' | This study |
| Δ144–157 Downstream | 5'-TATCTCTCGAGTATCTACGGGAACTGCTTCCG-3' | This study |
| Val33Arg-F | 5'-CCAAGAGGATTTAAGGAATTTTTACAATCCACAGCTCGC-3' | This study |
| Val33Arg-R | 5'-GCGAGCTGTGGATTGTAAAAATTCCTTAAATCCTCTTGG-3' | This study |
| Phe35His-F | 5'-CCAAGAGGATTTAGTGAATCATTACAATCCACAGCTCGC-3' | This study |
| Phe35His-R | 5'-GCGAGCTGTGGATTGTAATGATTCACTAAATCCTCTTGG-3' | This study |
| Asn37Ile-F | 5'-GGATTTAGTGAATTTTTACATTCCACAGCTCGCATCAGGG-3' | This study |
| Asn37Ile-R | 5'-CCCTGATGCGAGCTGTGGAATGTAAAAATTCACTAAATCC-3' | This study |
| Pro38Arg-F | 5'-GTGAATTTTTACAATCGACAGCTCGCATCAGG-3' | This study |
| Pro38Arg-R | 5'-CCTGATGCGAGCTGTCGATTGTAAAAATTCAC-3' | This study |
| Ser42Leu-F | 5'-CAATCCACAGCTCGCATTAGGGAAGCCTATTG-3' | This study |
| Ser42Leu-R | 5'-CAATAGGCTTCCCTAATGCGAGCTGTGGATTG-3' | This study |
| Asn54 Ile-F | 5'-GTCACGAACAATTTATCAAGGTGATCGTCATTCTCC-3' | This study |
| Asn54 Ile-R | 5'-GGAGAATGACGATCACCTTGATAAATTGTTCGTGAC-3' | This study |
| Pro62Gly-F | 5'-GGTGATCGTCATTCTGGAGATCTTCCAATTC-3' | This study |
| Pro62Gly-R | 5'-GAATTGGAAGATCTCCAGAATGACGATCACC-3' | This study |
| Asp63Val-F | 5'-GGTGAT CGTCATTCTCCAGTTCTTCCAATTCTTATACAAGG-3' | This study |
| Asp63Val-R | 5'-CCTTGTATAAGAATTGGAAGAACTGGAGAATGACG ATCACC-3' | This study |
| Leu64Arg-F | 5'-CGTCATTCTCCAGATCGTCCAATTCTTATACAAGG-3' | This study |
| Leu64Arg-R | 5'-CCTTGTATAAGAATTGGACGATCTGGAGAATGACG-3' | This study |
| Pro65Arg-F | 5'-CGTCATTCTCCAGATCTTCGAATTCTTATACAAGG-3' | This study |
| Pro65Arg-R | 5'-CCTTGTATAAGAATTCGAAGATCTGGAGAATGACG-3' | This study |
| Ile66Asn-F | 5'-CGTCATTCTCCAGATCTTCCAAATCTTATACAAGG AAATAG-3' | This study |
| Ile66Asn-R | 5'-CTATTT CCTTGTATAAGATTTGGAAGATCTGGAGAATGACG-3' | This study |
| Leu67Thr-F | 5'-CGTCATTCTCCAGATCTTCCAATTACGATACAAGGAAATAG-3' | This study |
| Leu67Thr-R | 5'-CTATTTCCTTGTATCGTAATTGGAAGATCTGGAGAATGACG-3' | This study |
| Leu75Ser-F | 5'-GGAAATAGATACCTTTCAGAGTATCAGATTGATGCTGTACC-3' | This study |
| Leu75Ser-R | 5'-GGTACAGCATCAATCTGATACTCTGAAAGGTATCTATTTCC-3' | This study |
| Arg59Leu-F | 5'-CGAACAAATTATCAAGGTGATCTTCATTCTCCAGATCTTCC-3' | This study |
| Arg59Leu-R | 5'-GGAAGATCTGGAGAATGAAGATCACCTTGATAATTTGTTCG-3' | This study |